MCID: MLG079
MIFTS: 43

Malignant Pleural Mesothelioma

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Malignant Pleural Mesothelioma

MalaCards integrated aliases for Malignant Pleural Mesothelioma:

Name: Malignant Pleural Mesothelioma 12 37 15 17 72
Malignant Mesothelioma of Pleura 12
Pleural Malignant Mesothelioma 55

Classifications:



External Ids:

Disease Ontology 12 DOID:7474
KEGG 37 H00015
NCIt 50 C7376
ICD10 33 C45.0
UMLS 72 C0812413

Summaries for Malignant Pleural Mesothelioma

KEGG : 37
Malignant mesothelioma (MM) is a rare but very aggressive tumor that arises from mesothelial cells lining the pleural, peritoneal and pericardial cavities. Malignant pleural mesothelioma (MPM) is the most common type, accounting for about 70% of all MM cases. Past asbestos exposure represents the major risk factor for MPM, as the link between asbestos fibres and MPM has been largely proved by epidemiological and experimental studies. Recently, simian virus 40 (SV40) has been implicated in the aetiology of MPM. The accumulation of numerous clonal chromosomal deletions in most MMs suggests a multistep process of tumorigenesis, characterized by the loss and/or inactivation of multiple tumor suppressor genes (TSGs). Cytogenetic and loss of heterozygosity (LOH) analyses of MMs have demonstrated frequent deletions of specific sites within chromosome arms 1p, 3p, 6q, 9p, 13q, 15q, and 22q. Furthermore, TSGs within two of these regions, i.e., p16/CDKN2A-p14ARF at 9p21 and NF2 at 22q12, are frequently altered in MMs. Mutations of the p53 gene (TP53) are occasionally observed in MMs.

MalaCards based summary : Malignant Pleural Mesothelioma, also known as malignant mesothelioma of pleura, is related to pleural disease and sarcomatoid mesothelioma, and has symptoms including fatigue, dyspnea and chest pain. An important gene associated with Malignant Pleural Mesothelioma is GAS5 (Growth Arrest Specific 5), and among its related pathways/superpathways is FGF signaling pathway. The drugs Vincristine and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and testes, and related phenotype is normal.

Disease Ontology : 12 A pleural cancer that has material basis in mesothelium cells.

Related Diseases for Malignant Pleural Mesothelioma

Diseases in the Benign Pleural Mesothelioma family:

Malignant Pleural Mesothelioma

Diseases related to Malignant Pleural Mesothelioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 269)
# Related Disease Score Top Affiliating Genes
1 pleural disease 31.8 SPP1 MSLN CALB2 BAP1
2 sarcomatoid mesothelioma 31.4 WT1 THBD NKX2-1
3 mesothelioma, malignant 31.4 WT1 TYMS THBD SPP1 NKX2-1 MSLN
4 peritoneal mesothelioma 31.1 WT1 THBD BAP1
5 pleural cancer 30.6 WT1 TYMS SPP1 MSLN CALB2 BAP1
6 pericardial mesothelioma 30.5 THBD MSLN CALB2
7 lung cancer susceptibility 3 30.2 NKX2-1 MSLN MET GAS5 CDH2 CALB2
8 clear cell renal cell carcinoma 30.0 PVT1 MET CALB2 BIRC5 BAP1
9 renal cell carcinoma, nonpapillary 29.9 WT1 PVT1 NKX2-1 MET GAS5
10 ovarian cancer 29.4 XIAP PVT1 MSLN GAS5 CDH2 BIRC5
11 pancreatic cancer 29.1 TYMS PVT1 MSLN MET GAS5 ENSG00000261211
12 lung cancer 29.0 XIAP TYMS SNHG7 PVT1 NKX2-1 MET
13 gastric cancer 28.0 TYMS SNHG8 SNHG7 PVT1 MET GAS5
14 benign mesothelioma 11.6
15 neutropenia 10.8
16 rare tumor 10.7
17 asbestosis 10.7
18 asbestos intoxication 10.7
19 adenocarcinoma 10.6
20 fallopian tube carcinosarcoma 10.6 WT1 CALB2
21 pneumothorax 10.6
22 virus-associated trichodysplasia spinulosa 10.5
23 diffuse peritoneal leiomyomatosis 10.5 WT1 CALB2
24 pleurisy 10.5
25 pleural empyema 10.5
26 severe combined immunodeficiency 10.5
27 peritoneal benign neoplasm 10.5 WT1 CALB2
28 malignant epithelial mesothelioma 10.5 WT1 THBD
29 venous hemangioma 10.5 WT1 CALB2
30 benign pleural mesothelioma 10.5
31 thrombocytosis 10.5
32 spindle cell liposarcoma 10.4 WT1 CALB2
33 respiratory failure 10.4
34 lymphohistiocytoid mesothelioma 10.4 THBD CALB2
35 esophagitis 10.4
36 thrombocytopenia 10.4
37 pericardium cancer 10.4 THBD MSLN CALB2
38 mixed germ cell-sex cord neoplasm 10.4 WT1 CALB2
39 rete testis adenocarcinoma 10.4 THBD NKX2-1 CALB2
40 pneumothorax, primary spontaneous 10.4
41 thymoma, familial 10.4
42 thymoma 10.4
43 lung disease 10.4
44 pulmonary embolism 10.4
45 back pain 10.4
46 rete testis neoplasm 10.4 THBD NKX2-1 CALB2
47 adenomatoid tumor 10.4 WT1 THBD CALB2
48 neurofibromatosis, type iv, of riccardi 10.3
49 wilms tumor 5 10.3
50 small cell carcinoma 10.3

Graphical network of the top 20 diseases related to Malignant Pleural Mesothelioma:



Diseases related to Malignant Pleural Mesothelioma

Symptoms & Phenotypes for Malignant Pleural Mesothelioma

UMLS symptoms related to Malignant Pleural Mesothelioma:


fatigue, dyspnea, chest pain, chills, malaise

MGI Mouse Phenotypes related to Malignant Pleural Mesothelioma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 normal MP:0002873 9.23 BIRC5 CALB2 MET MSLN NKX2-1 THBD

Drugs & Therapeutics for Malignant Pleural Mesothelioma

Drugs for Malignant Pleural Mesothelioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 173)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
2
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
3
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
5
Methylcobalamin Approved, Experimental, Investigational Phase 2, Phase 3 13422-55-4
6
Hydroxocobalamin Approved Phase 2, Phase 3 13422-51-0 11953898 15589840
7
Pemetrexed Approved, Investigational Phase 3 150399-23-8, 137281-23-3 60843 446556
8
leucovorin Approved Phase 3 58-05-9 143 6006
9
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
10
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
11
Bevacizumab Approved, Investigational Phase 3 216974-75-3
12
Pembrolizumab Approved Phase 3 1374853-91-4
13
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
14
Gemcitabine Approved Phase 3 95058-81-4 60750
15
nivolumab Approved Phase 2, Phase 3 946414-94-4
16
Ipilimumab Approved Phase 2, Phase 3 477202-00-9
17
Nintedanib Approved Phase 2, Phase 3 656247-17-5 56843413
18
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3 68-19-9 44176380
19
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
20
Cobalamin Experimental Phase 2, Phase 3 13408-78-1 6857388
21 Antiemetics Phase 3
22 Peripheral Nervous System Agents Phase 3
23 Mitomycins Phase 3
24
Liposomal doxorubicin Phase 3 31703
25 BB 1101 Phase 3
26 Vitamins Phase 2, Phase 3
27 Vitamin B 12 Phase 2, Phase 3
28 Vitamin B12 Phase 2, Phase 3
29 Micronutrients Phase 3
30 Trace Elements Phase 3
31 Gastrointestinal Agents Phase 3
32 Nutrients Phase 3
33 Autonomic Agents Phase 3
34 Folic Acid Antagonists Phase 3
35 Vitamin B9 Phase 3
36 Folate Phase 3
37 Nucleic Acid Synthesis Inhibitors Phase 3
38 Vitamin B Complex Phase 3
39 Mitogens Phase 3
40 Endothelial Growth Factors Phase 3
41 Interferon-alpha Phase 3
42 interferons Phase 3
43 Angiogenesis Inhibitors Phase 3
44 Angiogenesis Modulating Agents Phase 3
45 Interferon alpha-2 Phase 3
46 Tin Fluorides Phase 3
47 Immunosuppressive Agents Phase 3
48 Anti-Infective Agents Phase 3
49 Immunologic Factors Phase 3
50 Antibodies Phase 3

Interventional clinical trials:

(show top 50) (show all 176)
# Name Status NCT ID Phase Drugs
1 A Randomized Phase 3 Trial Comparing ALIMTA Plus Best Supportive Care Versus Best Supportive Care Alone in Previously Treated Patients With Locally Advanced or Metastatic Malignant Pleural Mesothelioma Completed NCT00190762 Phase 3 Pemetrexed
2 A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Oral Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) in Patients With Advanced Malignant Pleural Mesothelioma Previously Treated With Systemic Chemotherapy Completed NCT00128102 Phase 3 vorinostat;Placebo
3 A Randomized Controlled Trial of Active Symptom Control With or Without Chemotherapy in the Treatment of Patients With Malignant Pleural Mesothelioma Completed NCT00075699 Phase 3 cisplatin;mitomycin C;vincristine sulfate;vinorelbine tartrate
4 Phase III Study of Tomudex and Cisplatin Versus Cisplatin in Malignant Pleural Mesothelioma Completed NCT00004920 Phase 3 cisplatin;raltitrexed
5 NGR015: Randomized Double-blind Phase III Study of NGR-hTNF Plus Best Investigator's Choice (BIC) Versus Placebo Plus BIC in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma (MPM) Completed NCT01098266 Phase 3 NGR-hTNF plus Best Investigator's Choice (BIC);Placebo plus Best Investigator's Choice (BIC)
6 A Single-Blind Randomized Phase III Trial of MTA Plus Cisplatin Versus Cisplatin in Patients With Malignant Pleural Mesothelioma Completed NCT00005636 Phase 3 cisplatin;pemetrexed disodium
7 A Phase II-III Randomized Trial Pemetrexed-Cisplatin Chemotherapy With or Without Bevacizumab (Avastin), 15 mg/kg, for Malignant Pleural Mesothelioma (MPM) Completed NCT00651456 Phase 2, Phase 3 Standard Chemotherapy (Pemetrexed and Cisplatin);Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab
8 Phase III Trial of Single-Agent Pemetrexed (Alimta®) Versus the Combination of Carboplatin and Pemetrexed in Patients With Advanced Non-small-cell Lung Cancer and Performance Status of 2 Completed NCT01836575 Phase 3 Pemetrexed;Carboplatin
9 Randomized, Double-Blind, Phase 2/3 Study in Subjects With Malignant Pleural Mesothelioma With Low Argininosuccinate Synthetase 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study) Recruiting NCT02709512 Phase 2, Phase 3 ADI-PEG 20 plus Pem Cis
10 A Phase II/III Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma Recruiting NCT02784171 Phase 2, Phase 3 Cisplatin;Pemetrexed;Pembrolizumab
11 A Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab and Standard Chemotherapy Versus Bevacizumab and Standard Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma Recruiting NCT03762018 Phase 3 Carboplatin;Pemetrexed;Bevacizumab;Atezolizumab
12 A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma Recruiting NCT03710876 Phase 3 Celecoxib Oral Product;Gemcitabine
13 A Multicentre Randomised Phase III Trial Comparing Pembrolizumab Versus Standard Chemotherapy for Advanced Pre-treated Malignant Pleural Mesothelioma Active, not recruiting NCT02991482 Phase 3 Pembrolizumab;Gemcitabine;Vinorelbine
14 Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma Not yet recruiting NCT03918252 Phase 2, Phase 3 Nivolumab Injection;Ipilimumab Injection
15 LUME-Meso: Double Blind, Randomised, Multicentre, Phase II/III Study of Nintedanib in Combination With Pemetrexed / Cisplatin Followed by Continuing Nintedanib Monotherapy Versus Placebo in Combination With Pemetrexed / Cisplatin Followed by Continuing Placebo Monotherapy for the Treatment of Patients With Unresectable Malignant Pleural Mesothelioma Terminated NCT01907100 Phase 2, Phase 3 Nintedanib;Pemetrexed;Cisplatin;Cisplatin;Pemetrexed;Placebo
16 PIT: A Phase III Randomised Trial of Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma Following Invasive Chest Wall Intervention Terminated NCT01604005 Phase 3
17 A Randomized Stratified Multicentre Phase II Clinical Trial of Single Agent ADI-PEG 20TM (Pegylated Arginine Deiminase) in Patients With Malignant Pleural Mesothelioma Unknown status NCT01279967 Phase 2 ADI-PEG 20
18 A Pilot And Feasibility Trial Evaluating Two Different Chemotherapy Regimens In Combination With Intrapleural Adenoviral-Mediated Interferon-Alpha Gene Transfer For Malignant Pleural Mesothelioma Unknown status NCT01119664 Phase 1, Phase 2 SCH 721015
19 Four Versus Six Cycles of Pemetrexed/Platinum as a First Line Treatment of Malignant Pleural Mesothelioma; a Randomized Phase II Study Unknown status NCT02497053 Phase 2 pemetrexed/platinum chemotherapy;Pemetrexed/platinum chemotherapy
20 Phase II, A Study of Lung-Sparing Combined Modality Protocol for the Treatment for Malignant Pleural Mesothelioma: The Columbia Protocol Unknown status NCT00859495 Phase 2 Doxorubicin and cisplatin (intrapleural) + cisplatin and pemetrexed (systemic)
21 Phase II Study of Six Hours, Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma. Unknown status NCT01869023 Phase 2 Gemcitabine;Cisplatin
22 "Phase II Study: Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma " Unknown status NCT00886028 Phase 2 Liposomal doxorubicin;Cisplatin
23 Aggressive Multi-Modality Management of Malignant Pleural Mesothelioma Unknown status NCT00354393 Phase 2 cisplatin;methotrexate;vinorelbine ditartrate
24 A Phase II Study of the Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Malignant Pleural Mesothelioma Unknown status NCT02303899 Phase 2 Gemcitabine;Imatinib mesylate
25 Oxaliplatin (Eloxatin®) Plus Gemcitabine as First or Second-line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma: A Phase II Clinical Trial Unknown status NCT00859469 Phase 2 Oxaliplatin/Gemcitabine
26 A Phase II Trial to Assess the Safety, Immunological Activity of TroVax® Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma Unknown status NCT01569919 Phase 2 Pemetrexed;Cisplatin;Dexamethasone
27 A Phase II Study of the Association of Glivec® (Imatinib Mesylate, Formerly Known as STI 571) Plus Gemzar® (Gemcitabine) in Patients With Unresectable, Refractory, Malignant Mesothelioma Expressing Either PDGFR-Beta or C-Kit Unknown status NCT00551252 Phase 2 Imatinib mesylate plus Gemcitabine
28 Phase I-Ib Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin as First-line Therapy in Patients With Advanced or Metastatic Cancer Suitable for a Carboplatin and Pemetrexed Regimen as Part of Their Specific Therapy Unknown status NCT02049060 Phase 1, Phase 2 Tivantinib
29 Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM) Completed NCT00770120 Phase 2 everolimus
30 A Phase II Trial of Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma (MPM)) Completed NCT01112293 Phase 2 GC1008
31 Safety Confirmation Study of LY231514 Plus Cisplatin in Patients With Malignant Pleural Mesothelioma Completed NCT00386815 Phase 2 pemetrexed;cisplatin
32 Phase I/II Study of LY231514 Plus Cisplatin in Patients With Malignant Pleural Mesothelioma Completed NCT00251550 Phase 1, Phase 2 Pemetrexed;Cisplatin
33 NGR010: A Phase II Study of NGR-hTNF Administered as Single Agent Every 3 Weeks or Weekly in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma Previously Treated With no More Than One Systemic Therapeutic Regimen Completed NCT00484276 Phase 2 NGR-hTNF
34 Phase II Study of Carboplatin and Vinorelbine i.v. (Day 1) and Orally (Day 8) for Malignant Pleural Mesothelioma Completed NCT00272558 Phase 2 Carboplatin and Vinorelbine
35 A Phase I/II Clinical Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma Completed NCT02347917 Phase 1, Phase 2 BBI608;Pemetrexed;Cisplatin
36 A Phase I/IIa Study of the Safety, Tolerability and Biological Effect of Single and Repeat Administration of the Selectively Replication-competent Herpes Simplex Virus HSV1716 Into the Tumor-bearing Pleural Cavity (Intrapleural) in Patients With Inoperable Malignant Pleural Mesothelioma. Completed NCT01721018 Phase 1, Phase 2
37 An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma Completed NCT00738582 Phase 2 MORAb-009 (Amatuximab);Pemetrexed;Cisplatin
38 A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma Completed NCT01486368 Phase 2 PF-03446962
39 NGR019: Randomized Double-blind Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced Malignant Pleural Mesothelioma (MPM) Completed NCT01358084 Phase 2 NGR-hTNF;Placebo
40 A Single Arm Phase II Study of Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma: Interim Biopsy Analysis to Determine Efficacy. Acronym: NivoMes Study Completed NCT02497508 Phase 2 nivolumab
41 A Phase II Trial of Low-dose Gemcitabine in Prolonged Infusion and Cisplatin in Treatment of Malignant Pleural Mesothelioma Completed NCT01243632 Phase 2 Prolonged 6-hr infusion of gemcitabine
42 Phase II Study of GW786034 in Patients With Malignant Pleural Mesothelioma Completed NCT00459862 Phase 2 pazopanib hydrochloride
43 A Phase II Trial of Novel Oral Anti-Angiogenic Agent AZD2171 (NSC-732208) in Malignant Pleural Mesothelioma Completed NCT00243074 Phase 2 cediranib maleate
44 Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma Completed NCT00700336 Phase 1, Phase 2 pemetrexed, cisplatin and CBP501;pemetrexed and cisplatin
45 Phase II Study of Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity Completed NCT01024946 Phase 2 everolimus
46 Phase II Study of PXD101 (NSC 726630) as Second-Line Therapy for Treatment of Patients With Malignant Pleural Mesothelioma Completed NCT00365053 Phase 2 belinostat
47 A Phase II Study of Oral EGFR Tyrosine Kinase Inhibitor OSI-774 (NSC-718781) in Patients With Malignant Pleural Mesothelioma Completed NCT00039182 Phase 2 erlotinib hydrochloride
48 Phase II Clinical Study of a Liposome Entrapped Cisplatin Analog (L-NDDP) Administered Intrapleurally in Patients With Malignant Pleural Mesothelioma Completed NCT00004033 Phase 2 liposomal NDDP
49 A Phase II Study of Sunitinib (SU11248; NSC 736511; IND 74019) in Patients With Advanced Malignant Pleural Mesothelioma Completed NCT00392444 Phase 2 sunitinib malate
50 A Phase II Feasibility Trial of Induction Chemotherapy Followed by Extrapleural Pneumonectomy and Postoperative Radiotherapy in Patients With Malignant Pleural Mesothelioma Completed NCT00227630 Phase 2 cisplatin;pemetrexed disodium

Search NIH Clinical Center for Malignant Pleural Mesothelioma

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Carboplatin

Genetic Tests for Malignant Pleural Mesothelioma

Anatomical Context for Malignant Pleural Mesothelioma

MalaCards organs/tissues related to Malignant Pleural Mesothelioma:

41
Lung, T Cells, Testes, Endothelial, Lymph Node, Brain, Liver

Publications for Malignant Pleural Mesothelioma

Articles related to Malignant Pleural Mesothelioma:

(show top 50) (show all 3655)
# Title Authors PMID Year
1
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. 9 38
20075387 2010
2
Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. 9 38
20177021 2010
3
Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma. 9 38
19302997 2009
4
Osteopontin modulates malignant pleural mesothelioma cell functions in vitro. 9 38
19528482 2009
5
Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. 9 38
19201924 2009
6
Osteopontin is not a specific marker in malignant pleural mesothelioma. 9 38
19634115 2009
7
Comparison of different clones (WT49 versus 6F-H2) of WT-1 antibodies for immunohistochemical diagnosis of malignant pleural mesothelioma. 9 38
19516197 2009
8
Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin. 9 38
18394747 2008
9
Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma. 9 38
18827603 2008
10
Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. 9 38
18670302 2008
11
Prognostic role of osteopontin expression in malignant pleural mesothelioma. 9 38
18550471 2008
12
Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: a meta-analysis. 9 38
18422869 2008
13
[Renal cell carcinoma with malignant pleural mesothelioma after asbestos exposure: a case report]. 9 38
18051806 2007
14
Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. 9 38
17646232 2007
15
A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. 9 38
17671130 2007
16
Polymorphisms of glutathione-S-transferase M1 and manganese superoxide dismutase are associated with the risk of malignant pleural mesothelioma. 9 38
17290392 2007
17
Osteopontin is linked to p65 and MMP-9 expression in pulmonary adenocarcinoma but not in malignant pleural mesothelioma. 9 38
17493236 2007
18
Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. 9 38
17504993 2007
19
Molecular basis of antifolate resistance. 9 38
17333344 2007
20
Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma. 9 38
17279584 2007
21
Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma. 9 38
16294031 2006
22
L1CAM, INP10, P-cadherin, tPA and ITGB4 over-expression in malignant pleural mesotheliomas revealed by combined use of cDNA and tissue microarray. 9 38
15447976 2005
23
The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. 9 38
12940775 2003
24
Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment. 9 38
12800189 2003
25
Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. 9 38
12479365 2002
26
Detection and quantification of SV40 large T-antigen DNA in mesothelioma tissues and cell lines. 9 38
11956641 2002
27
Up-regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma. 9 38
11307155 2001
28
Manganese superoxide dismutase as a diagnostic marker for malignant pleural mesothelioma. 9 38
10737384 2000
29
A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours. 9 38
9639123 1998
30
Manganese superoxide dismutase in healthy human pleural mesothelium and in malignant pleural mesothelioma. 9 38
9533946 1998
31
Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma. 9 38
9692834 1998
32
Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma. 9 38
1357974 1992
33
Commentary: Adjuvant intensity-modulated radiation therapy for malignant pleural mesothelioma: Suspension of intention. 38
31030959 2019
34
Return to intended oncologic treatment after surgery for malignant pleural mesothelioma. 38
31430846 2019
35
Managing malignant pleural mesothelioma: experience and perceptions of health care professionals caring for people with mesothelioma. 38
30684047 2019
36
Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort. 38
31279641 2019
37
Management of Malignant Pleural Mesothelioma in the Elderly Population. 38
31011908 2019
38
Molecular characterization of localized pleural mesothelioma. 38
31371807 2019
39
On the diagnosis of malignant pleural mesothelioma: A necropsy-based study of 171 cases (1997-2016). 38
29714657 2019
40
Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma. 38
31078776 2019
41
On the diagnosis of malignant pleural mesothelioma: a necropsy-based study of 171 cases (1997-2016). 38
30592233 2019
42
On the diagnosis of malignant pleural mesothelioma: A necropsy-based study of 171 cases (1997-2016). 38
31418338 2019
43
Dropwort-induced metabolic reprogramming restrains YAP/TAZ/TEAD oncogenic axis in mesothelioma. 38
31399037 2019
44
What can independent research for mesothelioma achieve to treat this orphan disease? 38
31262194 2019
45
A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Taskforce. 38
31136816 2019
46
Vascular-targeted low dose photodynamic therapy stabilizes tumor vessels by modulating pericyte contractility. 38
30779366 2019
47
Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905). 38
31386610 2019
48
Fatal Anti-Ma2 Encephalitis Related to Treatment of Malignant Pleural Mesothelioma With a Combination of Anti-Programmed Death 1 and Anti-Cytotoxic T-Lymphocyte Associated Protein 4 Antibodies. 38
31345342 2019
49
Induction of gamma-glutamyltransferase activity and consequent prooxidant reactions in human macrophages exposed to crocidolite asbestos. 38
31388672 2019
50
[Hyperthermic intrathoracic chemotherapy in thoracic surgery]. 38
31218434 2019

Variations for Malignant Pleural Mesothelioma

Copy number variations for Malignant Pleural Mesothelioma from CNVD:

7 (show all 35)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13406 1 1 2300000 Loss Pleural malignant mesothelioma
2 21839 1 16200000 28000000 Loss Pleural malignant mesothelioma
3 33951 1 50700000 61300000 Amplification Pleural malignant mesothelioma
4 35953 1 69700000 116100000 Loss Pleural malignant mesothelioma
5 35955 1 69700000 116100000 Loss CLCA1 Pleural malignant mesothelioma
6 35957 1 69700000 116100000 Loss CLCA2 Pleural malignant mesothelioma
7 35959 1 69700000 116100000 Loss CLCA3 Pleural malignant mesothelioma
8 35961 1 69700000 116100000 Loss CLCA4 Pleural malignant mesothelioma
9 35963 1 69700000 116100000 Loss COL11A1 Pleural malignant mesothelioma
10 35965 1 69700000 116100000 Loss TGFBR3 Pleural malignant mesothelioma
11 35967 1 69700000 120600000 Loss Pleural malignant mesothelioma
12 37057 1 84900000 107200000 Loss Pleural malignant mesothelioma
13 69953 12 56600000 58100000 Gain Pleural malignant mesothelioma
14 75173 13 17900000 45800000 Loss BRCA2 Pleural malignant mesothelioma
15 85739 14 50900000 107349540 Loss CCNK Pleural malignant mesothelioma
16 85741 14 50900000 107349540 Loss CDKN3 Pleural malignant mesothelioma
17 113646 17 44900000 81195210 Gain ERN1 Pleural malignant mesothelioma
18 113648 17 44900000 81195210 Gain MAP3K3 Pleural malignant mesothelioma
19 113650 17 44900000 81195210 Gain PRKCA Pleural malignant mesothelioma
20 113652 17 44900000 81195210 Gain SMARCD2 Pleural malignant mesothelioma
21 175423 3 39400000 63700000 Loss CACNA2D3 Pleural malignant mesothelioma
22 175425 3 39400000 63700000 Loss CTNNB1 Pleural malignant mesothelioma
23 175427 3 39400000 63700000 Loss MLH1 Pleural malignant mesothelioma
24 175772 3 44100000 44200000 Loss Pleural malignant mesothelioma
25 187515 4 50400000 191154276 Loss Pleural malignant mesothelioma
26 191706 5 1 48400000 Gain Pleural malignant mesothelioma
27 204730 6 114600000 118300000 Loss HDAC2 Pleural malignant mesothelioma
28 204732 6 114600000 118300000 Loss MARCKS Pleural malignant mesothelioma
29 217076 7 1 4500000 Gain Pleural malignant mesothelioma
30 234872 8 139900000 146364022 Gain Pleural malignant mesothelioma
31 250027 9 19900000 25600000 Loss C9orf14 Pleural malignant mesothelioma
32 250030 9 19900000 25600000 Loss CDKN2A Pleural malignant mesothelioma
33 250032 9 19900000 25600000 Loss CDKN2B Pleural malignant mesothelioma
34 250070 9 19900000 33200000 Loss Pleural malignant mesothelioma
35 251885 9 33200000 36300000 Gain Pleural malignant mesothelioma

Expression for Malignant Pleural Mesothelioma

Search GEO for disease gene expression data for Malignant Pleural Mesothelioma.

Pathways for Malignant Pleural Mesothelioma

Pathways related to Malignant Pleural Mesothelioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.47 SPP1 MET CDH2

GO Terms for Malignant Pleural Mesothelioma

Sources for Malignant Pleural Mesothelioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....